: Clostridium perfingens bloodstream infections (BSIs) can be associated with high mortality rates. We performed a subanalysis of all C. perfringens BSIs enrolled during a multicentric retrospective observational study (ITANAEROBY). Data were collected from January 2016 to December 2020. C. perfringens BSIs were 134 (134/1960, 6.8 %). The highest resistance rate was observed for clindamycin (26/120, 21.6 %), penicillin (11/71, 15.4 %) and metronidazole (14/131, 10.7 %). In conclusion, C. perfringens reduced susceptibility phenotype to first-line therapy.
A subanalysis of Clostridium perfringens bloodstream infections from a 5-year retrospective nationwide survey (ITANAEROBY) / Geremia, N., Sanson, G., Principe, L., Antonello, R.M., Zerbato, V., Luzzati, R., Maraolo, A.E., Giacobbe, D.R., Sepulcri, C., Ambretti, S., Aschbacher, R., Bartolini, L., Bernardo, M., Bielli, A., Busetti, M., Carcione, D., Camarlinghi, G., Carretto, E., Cassetti, T., Chilleri, C., et al.. - In: ANAEROBE. - ISSN 1075-9964. - 90:(2024). [10.1016/j.anaerobe.2024.102901]
A subanalysis of Clostridium perfringens bloodstream infections from a 5-year retrospective nationwide survey (ITANAEROBY)
Maraolo, Alberto EnricoMembro del Collaboration Group
;Bernardo, Mariano;
2024
Abstract
: Clostridium perfingens bloodstream infections (BSIs) can be associated with high mortality rates. We performed a subanalysis of all C. perfringens BSIs enrolled during a multicentric retrospective observational study (ITANAEROBY). Data were collected from January 2016 to December 2020. C. perfringens BSIs were 134 (134/1960, 6.8 %). The highest resistance rate was observed for clindamycin (26/120, 21.6 %), penicillin (11/71, 15.4 %) and metronidazole (14/131, 10.7 %). In conclusion, C. perfringens reduced susceptibility phenotype to first-line therapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1075996424000842-main.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
434.4 kB
Formato
Adobe PDF
|
434.4 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
